Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemGenex and MolecularMD, a provider of drug resistance mutation screening, are to work together to identify chronic myeloid leukemia patients with the T315I bcr-abl mutation for participation in ChemGenex's phase II/III study of Ceflatonin, in patients with this mutation.
Subscribe to our email newsletter
The T315I point mutation is attracting significant attention globally as T315I expressing cells are resistant to Novartis’ tyrosine kinase inhibitor, Gleevec, meaning chronic myeloid leukemia (CML) patients who develop this mutation no longer respond to Gleevec.
In addition, preliminary data suggest that CML patients with the T315I point mutation also fail to respond to treatment with either of two second generation tyrosine kinase inhibitors currently in clinical development.
“CML patients typically develop genetic mutations as their disease progresses, requiring accurate and reliable molecular diagnosis to determine if alternative therapies or a combination of drugs might be needed, as well as to fully assess the efficacy of their treatment,” said Dr Greg Collier, ChemGenex CEO.